Alchemia could double in value after investors endured a volatile two weeks. The biotech company’s shares surged 30 per cent to an 18-month high of 80¢ on July 13, when a partner that uses Alchemia technology to make Fondaparinux secured approval to sell the drug in the US. Profit taking saw the stock drift back towards 70¢ but brokers still see plenty of upside, especially if phase 3 trials for cancer treatment HyACT are successful.